User profiles for "author:Pui San Tan"
 | Pui San TanUniversity of Nottingham Malaysia Verified email at nottingham.edu.my Cited by 2488 |
The challenge of antimicrobial resistance: what economics can contribute
BACKGROUND Antimicrobial resistance (AMR) is increasing, driven by widespread
antibiotic use. The wide availability of effective antibiotics is under threat, jeopardizing …
antibiotic use. The wide availability of effective antibiotics is under threat, jeopardizing …
Clinician‐targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews
SKG Tonkin‐Crine, P San Tan… - Cochrane Database …, 2017 - cochranelibrary.com
Background Antibiotic resistance is a worldwide health threat. Interventions that reduce
antibiotic prescribing by clinicians are expected to reduce antibiotic resistance. Disparate …
antibiotic prescribing by clinicians are expected to reduce antibiotic resistance. Disparate …
Impact of point-of-care C reactive protein in ambulatory care: a systematic review and meta-analysis
JY Verbakel, JJ Lee, C Goyder, P San Tan… - BMJ open, 2019 - bmjopen.bmj.com
Objective The aim of this review was to collate all available evidence on the impact of point-
of-care C reactive protein (CRP) testing on patient-relevant outcomes in children and adults …
of-care C reactive protein (CRP) testing on patient-relevant outcomes in children and adults …
[HTML][HTML] Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study
Background Previous studies suggested that the prevalence of chronic respiratory disease
in patients hospitalised with COVID-19 was lower than its prevalence in the general …
in patients hospitalised with COVID-19 was lower than its prevalence in the general …
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
J Hippisley-Cox, D Young, C Coupland, KM Channon… - Heart, 2020 - heart.bmj.com
Background There is uncertainty about the associations of angiotensive enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied …
inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied …
[HTML][HTML] Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort
Background Conflicting evidence has emerged regarding the relevance of smoking on risk
of COVID-19 and its severity. Methods We undertook large-scale observational and …
of COVID-19 and its severity. Methods We undertook large-scale observational and …
[HTML][HTML] Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B. 1.1. 7 in England: an observational cohort study
Background A more transmissible variant of SARS-CoV-2, the variant of concern 202012/01
or lineage B. 1.1. 7, has emerged in the UK. We aimed to estimate the risk of critical care …
or lineage B. 1.1. 7, has emerged in the UK. We aimed to estimate the risk of critical care …
Association between race and COVID-19 outcomes among 2.6 million children in England
Importance Although children mainly experience mild COVID-19 disease, hospitalization
rates are increasing, with limited understanding of underlying factors. There is an …
rates are increasing, with limited understanding of underlying factors. There is an …
Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer
Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …
[HTML][HTML] Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …